உயர் இயக்கம் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article WASHINGTON, March 16, 2021 /PRNewswire/ An article published in Experimental Biology and Medicine (Volume 246, Issue 6, March, 2021) reports a new nucleic acid-based approach for therapeutics targeting inflammation. The study, led by Dr. Anthony Bell Jr, in the Department of Chemistry and Biochemistry at the University of San Diego in San Diego, CA (USA), reports four novel cruciform DNA ligands that exhibit increased nuclease-resistance, thermostability, and target-binding affinity.  HMGB1 (High Mobility Group B1) is an important molecular target in multiple human diseases including infectious diseases, ischemia, immune disorders, neurodegenerative diseases, metabolic disorders, and cancer. HMGB1 plays two different but critical roles inside and outside of cells. Inside cells, HMGB1 bends DNA into arrangements or scaffolds that facilitate gene expression. Outside cells, HMGB1 functions as a proinflammatory cytokine that can be either a friend or foe

San diegoUnited statesUniversity of san diegoStevenr goodmanAnthony bell jrDepartment of chemistrySociety of experimental biologyHigh mobility groupExperimental biologyExperimental biology and medicineசான் டியாகோஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் சான் டியாகோஅந்தோணி மணி ஜூனியர்துறை ஆஃப் வேதியியல்சமூகம் ஆஃப் சோதனை உயிரியல்